Earnings ·
Aurinia raises 2026 revenue guidance to $325M-$330M as Q3 sales climb 14% to $83.7M
AUPHAurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals reported third-quarter total revenue of $83.7 million, a 14% increase from the prior-year period, driven by $79.4 million in net product sales for its lupus nephritis therapy LUPKYNIS. The company also raised its full-year 2026 total revenue guidance to a range of $325 million to $330 million and narrowed its net product sales outlook to $310 million to $315 million. Net income for the quarter was $31.7 million, with diluted earnings per share remaining flat at $0.23 compared to the same period last year. Aurinia is a biopharmaceutical company focused on delivering therapies for autoimmune diseases.